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Abstract 
 
The pathophysiology of systemic inflammatory response syndrome (SIRS) had been described to involve various 
strong oxidative reactions affecting the status and progress of the patients. Antioxidant therapy had been suggested in 
many studies involving SIRS management. The objective of this study was to compare the role of vitamin E 
Tocotrienol and vitamin E Tocopherol combined with vitamin C as antioxidant therapy in the management of 
critically ill patients diagnosed with SIRS, admitted to the intensive care unit and high dependency wards of 
Universiti Kebangsaan Malaysia Medical Centre (UKMMC). It was a single blind randomized clinical trial with a 
total of 72 patients in which 44.4% Malays, 34.7% Chinese, 19.4% Indians and 1.4% others with 59.7% males and 
40.3% females were recruited. Patients in TRI E group received Tocotrienol with Vitamin C while TOCO group 
received Tocopherol with Vitamin C and a control group did not receive any antioxidant. The clinical parameters 
(heart rate, respiratory rate, systolic blood pressure) showed improvements with significant difference at the end of 
study (post-intervention) as compared to admission (pre-intervention).Whereas, the sepsis (temperature, PCT, CRP 
and WBC) and oxidative stress (8-OHdG/Creatinine) parameters showed improvements with significant difference at 
the end of study (post-intervention) as compared to admission (pre-intervention). The TRI E group showed obvious 
improvement in clinical, sepsis and oxidative stress parameters, as compared to TOCO and control groups. This 
study showed that Vitamin E Tocotrienol and Vitamin E Tocopherol in combination with Vitamin C demonstrated 
significant improvement in the clinical and laboratory parameters during the management of SIRS. Therefore, 
Vitamin E in combination with Vitamin C had therapeutic benefits in the treatment of critically ill patients with 
SIRS. 
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Introduction 
 
Systemic Inflammatory Response Syndrome (SIRS) is 
defined as a widespread inflammatory response that 
manifested as an array of clinical insults. It is 
clinically recognized by the presence of two or more 
of the following:  temperature > 38°C or < 36°C, heart 
rate > 90 beats/min, respiratory rate > 20 breaths/min  
 
 
or arterial carbon dioxide partial pressure (Pa CO2) < 
32 mmHg and white blood count >12,000 cells/mm3 or 
< 4000 cells/mm3. Severe SIRS is associated with 
organ dysfunction, hypo perfusion, or hypotension 
which may lead to shock (1). SIRS has been found as 
an important etiology for the morbidity and mortality  
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Table 1: Inclusion and exclusion criteria 
 
Inclusion criteria Exclusion criteria 
ICU,HDU,HDS patient defined SIRS 
criteria 
When expected or anticipated survival were less than 48 hours 
diagnosed by the attendant doctors.  
Age limit: >16 and < 76 
 
Bile and GIT absorption disorders interfering with fat soluble 
enteral medications documented on patient workout by medical 
teams. 
 Any Other Contraindications for enteral medications documented 
on patient workout by medical teams 
 Apache II ICU scores more than 13 or less than 8 
 
among the critically ills after trauma, burns, and sepsis 
(2). SIRS presenting with definitive evidence of 
infection is recognized as sepsis.  
 
There were many approaches for treatment of SIRS 
and its related consequences. However, those 
therapeutic strategies are not always able to control the 
excessive inflammatory response, either because of 
global immune suppression or agents used, targeted 
specific inflammatory mediator ineffectively. It was 
suggested, by modulating the activation of 
inflammatory cells, even at very proximal stages of 
activation such as during inflammatory stimulus signal 
transduction may control excessive inflammation (3). 
The importance of oxidative stress in the early phases 
of critical illness is underscored by the relative 
antioxidant depletion reported in patients admitted to 
the ICU as they are recorded to have reduced total 
antioxidant capacity (4). There is a strong relationship 
between a decrease in antioxidant capacity and the 
severity of illness and increasing levels of organ 
dysfunction (5).  
 
The evidence for oxidative stress in the critically ill 
patient, coupled with direct oxidative tissue injury and 
induction of the systemic inflammatory response 
provides a sound biologic rationale for antioxidant 
supplementation (6). Vitamin E is the principal 
antioxidant of the lipid domains of the body such as 
cellular membranes. It is a peroxyl radical scavenger 
protecting the polyunsaturated fatty acids within 
membrane phospholipids and in plasma lipoproteins, 
against oxidation. All forms of vitamin E possess 
antioxidant activity. The relative antioxidant activity 
of the tocopherols with regards to peroxyl radical 
scavenging is α > β > γ > δ. The order is similar 
among the tocotrienols (21). The aim of this study is to 
compare the effectiveness of tocotrienol rich fraction 
and α-tocoferol with combination of vitamin C as 
antioxidant in the treatment of Systemic Inflammatory 
Response Syndrome (SIRS). 
 
Materials and Methods 
 
Subjects 
 
The ethic approval was obtained from the Universiti 
Kebangsaan Malaysia Research and Ethics committee. 
This is a randomized single-blinded study. It included 
patients that were admitted to ICU, HDU, and HDS fit 
with at least two or more of the following SIRS criteria: 
temperature >38°C or < 36°C, heart rate > 90 beats/min, 
respiratory rate > 20 breaths/min or arterial carbon 
dioxide partial pressure (Pa CO2) < 32 mmHg, white 
blood count >12,000 cells/mm3 or <4000 cells/mm3. 
Patients were chosen according to inclusion and 
exclusion criteria as shown in Table 1. Written informed 
consent was obtained from 72 patients diagnosed with 
SIRS that fulfill the inclusion criteria aged between 16 
and 76 years who admitted to UKMMC ICU, HDU and 
HDS. These patients were recruited and randomized 
into the following three groups: 1) tocotrienol rich 
fraction (TRI E); 2) α-tocoferol (TOCO); 3) no 
medication (control) according to the sequence of 
enrollment. 
 
Vitamin E and C administration protocol 
 
All intervention groups received study medications 3 
times daily for the 9 days, while the control group 
received no medication. The intervention group, TRI E 
received tocotrienol (TRF) with vitamin C and TOCO 
received α-tocoferol with vitamin C. All patients 
continued to have their conventional therapy for the 
clinical presentation or diagnosis. TRI E group 
received TRF 400 IU (Sime Darby Sdn. Bhd) and 
TOCO group received α-tocoferol 400 IU (Sime 
Darby Sdn. Bhd) 8 hourly in oil form via nasogastric 
tube or soft gel capsules (Hovid Sdn Bhd). Both TRI E 
and TOCO groups’ patients received vitamin C 500mg 
every 8 hourly. 
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Measurements 
 
After randomization, patients were subjected to base 
line measurements in which clinical measurements of 
temperature in celcius (°C), heart rate in beats/minute, 
blood pressure in mmHg and respiratory rate in 
cycles/minute. The urine output in ml/hour, Apache II 
score, inotropics & vasopressors used were also 
recorded. Blood samples were sent for baseline blood 
tests: PCT, CRP, LFT, WBC, ABG and PT and APTT. 
The urine sample was collected for 8OHdG test from 
every patient according to the study plan. Blood 
samples were collected from all the groups (72 
patients) at admission and at day 9 after intervention. 
Urine is collected and stored immediately at – 20°C 
and centrifuged prior to 8OHdG test to purify it from 
any sediment. Patients who had serious persistent 
abnormal LFT, PT, APTT values or severe acidosis at 
the beginning of the study or in the course of the study 
were either not selected or dropped from the study.  
 
The WBC analysis was performed in pathology 
hematology laboratory of UKMMC and blood run 
through Coulter LH 750 Analyzer with 2 models 
which are LH2 –LH 750 and LH2 – 755. LFT, PT, 
APTT, CRP and PCT analysis were performed in 
pathology biochemical laboratory of UKMMC. All of 
LFT, PT, APTT, CRP and PCT blood samples were 
centrifuged at room temperature with 4000 Rpm for 5 
minutes and supernatants were taken for analysis. PT 
and APTT were carried out by STA Compact 
Diagnostica Stago. LFT and CRP were carried out by 
either ROCHE COBAS INTEGRA 800 or ROCHE 
COBAS 8000. PCT was carried out by KRYPT 
B.R.A.H.M.S and ABG was carried out by ABL 800 
BASIC Radiometer Copenhagen. 
 
The 8-OHdG ELISA kit is a competitive in vitro 
enzyme linked immunosorbent assay used for 
quantitative measurement of the oxidative DNA 
product of 8-OHdG in the tissue, urine and other 
biological fluids. The 8-OHdG analysis was performed 
in microbiology immunology laboratory of UKMMC 
and urine run through 8-hydroxy-2- deoxy Guanosine 
EIA kit (Cayman Chemical Co.).  
 
Statistical Analysis             
 
The data collected from various quantitative 
parameters were presented as a mean ± standard error 
of the mean (SEM) of sample size. The parametric 
mean was compare using paired Student’s T tests 
where it usually compares each parameter before and 
after the intervention, in each group individually. One-
way ANOVA test was used to compare the results 
between 3 groups (TRI E, TOCO and Control). Chi-
square was used to analyze the results of Inotropes as 
results was by coded by yes or no type of data All 
statistical analysis was performed using the version 
17.0 SPSS software. The differences at p<0.05 was 
considered significant. 
 
Results  
 
Demographical  
 
This study included 72 randomized patients that were 
admitted to the ICU, HDU and HDS. Of these patients, 
48 patients received antioxidant supplements and were 
grouped into either TRI E or TOCO, while another 24 
patients received critical care management without 
antioxidant supplements. 
 
The study population consisted mainly of middle aged 
men and predominantly of Malay race followed by 
Chinese then Indian. Majority of the patients (48%) 
were admitted to ICU. Statistically, there were no 
significant differences between patients’ age (42.88 ± 
9.83, 40.04 ± 9.56, 42.04 ± 11.46), weight ((70.54 ± 
13.39, 74.04 ± 6.56, 69.56 ± 11.47) and APACHE II 
score (11.29 ± 1.16, 11.13 ± 1.23, and 11.17 ± 1.27) 
for TRI E, Control and TOCO groups, respectively 
(Table 2). 
 
Hemodynamic parameters  
 
The haemodynamic parameters in all intervention 
group (TRI E, TOCO or control) showed significant 
changes at the end of study (post-intervention) as 
compared to admission (pre-intervention) results for 
all parameters except systolic and diastolic blood 
pressure (Table 3.1). 
 
In the TRI E group, heart rate decreased while urine 
output increased and both were statistically significant 
(p<0.001). Use of inotropes decreased, as at the end of 
the study 24 patients were not on inotropes (p<0.001). 
The same changes were documented in the control 
group for heart rate and urine output (p<0.001). 
However, the number of patients on inotropes was 
statistically not significant. In the Toco group, the 
mean heart rate decreased and the number of patients 
on inotropes was less. Both changes in heart rate and 
the use of inotropes were statistically significant with 
p<0.001 and p<0.05 respectively, whilst the decrease 
in mean urine output was not. 
 
There was improvement in blood pressure where the 
systolic and diastolic blood pressures was increased in 
the control and TRI E groups, however the blood 
pressure was slightly decreased in the TOCO group. 
There was no significant difference in both systolic  
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Table 2: Demographical distribution, data are expressed as mean ± SD. with no significant differences between patients’ age, 
weight and APACHE II for TRI E, Control and TOCO groups, respectively. 
 
 
TRI E 
n=24 
TOCO 
n=24 
Control 
n=24 
p value 
Age, years  42.88 ± 9.83 40.04 ± 9.56 42.04 ± 10.24 0.62 
Weight, kg  70.54 ± 13.39 74.04 ± 6.56 69.56 ± 11.47 0.33 
Race:  
Malay  
Chinese  
Indian  
Others  
 
11 
7 
5 
1 
 
12 
8 
4 
0 
 
9 
10 
5 
0 
 
Location:  
ICU:HDS:HDU 
 
17:4:3 
 
16:3:5 
 
15:5:4 
 
APACHE II Score  11.29 ± 1.16 11.17 ± 1.21 11.13 ± 1.23 0.89 
 
Table 3.1: Pre and post-intervention results of hemodynamic parameters, data are expressed as mean ± SD with significant 
statistical analysis *p<0.05 and **p<0.001. 
 
 Parameters  TRI E TOCO Control 
Heart rate (admission)  131.33 ± 25.44** 119.67 ± 18.83** 114.92 ± 24.39** 
Heart rate (end of study)  86.54 ± 7.81** 96.33 ± 13.18** 92.08 ± 12.22 ** 
Systolic blood pressure (admission)  
Systolic blood pressure (end of study)  
117.54 ± 32.13 
129.67 ± 7.47 
125.58 ± 26.56 
117.33 ± 13.89 
120.42 ± 25.26 
125.92 ± 12.49 
Diastolic blood pressure (admission)  71.33 ± 17.22 75.04 ± 17.35 74.50 ± 19.59 
Diastolic blood pressure  (end of study)  76.17 ± 10.51 68.75 ± 13.30 76.33 ± 11.24 
Urine output (admission)  55.42 ± 24.71** 110.21 ± 121.44 79.58 ± 55.11 ** 
Urine output (end of study)  121.96 ± 55.76** 138.25 ± 92.06 109.38 ± 71.93** 
 
and diastolic blood pressures in all groups. The blood 
pressure was stable on admission and maintained until 
end of the study, with or without inotropes support. 
The use of inotropes decreased in both TRI E and 
TOCO groups and the difference was significance with 
p< 0.001 and p< 0.05, respectively. 
 
When comparisons were made in between the three 
groups, it showed significance difference for all 
parameters except for the urine output (Table 3.2). 
Comparing the means of inotropic agent used between 
the groups showed significant relationship for TRI E 
group over TOCO and control group (p<0.02, 
p<0.001) (Table 3.3). 
 
The respiratory rate at the end of the study showed 
significant changes in all the groups. Comparison of 
the means between all groups showed significant 
difference with p value of <0.001. The TRI E group 
showed obvious improvement in respiratory rate as 
compared to TOCO and control groups (Table 3.4). 
Laboratory parameters  
 
Sepsis parameters 
 
The patients in TRI E and Control group had shown 
significant decrease in temperature at the end of study 
as compare to admission with the p value of < 0.001. 
However, the temperature changes in TOCO group 
were not significant although it showed improvement. 
There were significant different temperature in 
between TRI E and TOCO group with p value < 0.02 
(Table 4). 
 
The plasma level of procalcitonin (PCT) at the end of 
study as compare to admission showed significant 
reduction in all intervention groups with p value of 
less than 0.001, 0.001 and 0.05 respectivel. However, 
there were no statistical differences of PCT level in 
between all the three groups at the end of study (Fig. 
1). 
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Table 3.2: Comparison post-intervention results of hemodynamic parameters in all intervention groups, data are expressed as 
mean ± SD with significant statistical analysis *p<0.05 and **p<0.001. 
 
 TRI E TOCO Control p 
Heart rate  86.54 ± 7.81 96.33±13.18 92.08±12.22 0.01* 
Systolic blood pressure  129.67 ± 7.47 117.33±13.89 125.92±12.49 0.001** 
Diastolic blood pressure  76.17±10.51 68.75±13.30 76.33±11.24 0.04* 
Urine output  121.96±55.76 138.25±92.06 109.38±71.93 0.41 
 
Table 3.3: Post-intervention results of inotropes used by all intervention groups, data are expressed as percentage (%) with 
significant statistical analysis *p<0.05 and **p<0.001. 
 
Inotropes 
GROUP 
2 p 
TRI E TOCO 
No  24 (100) 19 (79.2) 5.581a 0.02* 
Yes  0 5 (20.8) 
 
  
   TOCO Control   
No  19 (79.2) 15 (62.5) 1.61 0.20 
Yes  5 (20.8) 9 (37.5) 
     TRI E Control   
No  24 (100) 15 (62.5) 11.07 0.001** 
Yes  0 9 (37.5) 
   
Table 3.4: Pre and post-intervention results for respiratory rate of all intervention groups, data are expressed as mean ± SD with 
significant statistical analysis *p<0.05 and **p<0.001. 
 
 TRI E Control Toco 
Respiratory rate at admission 31.59±9.33 38.13±8.71 35.71±7.34 
Respiratory rate at end of study 15.14±1.88 19.22±2.43 22.00±2.86 
 p value 0.001** 0.001** 0.001** 
 
Table 4: Pre and post-intervention results of temperature, data are expressed as mean ± SD with significant statistical analysis 
*p<0.05 and **p<0.001. 
 
Temperature TRI E TOCO Control 
Admission  38.63±1.19 37.91±1.18 38.27±1.43 
End of study  36.96±0.15 37.49±0.78 37.27±0.79 
p value   0.001** 0.12 0.001** 
 
The plasma level of C-reactive protein (CRP) showed 
significant reduction in each group at the end of study 
as compare to admission with p value < 0.001 for TRI 
E, Control and TOCO groups. The mean CRP of the 
TRI E group and the TOCO group showed significant 
difference with p value of <0.03 (Fig. 1). 
 
 
 
 
The white blood cell (WBC) count showed significant 
reduction in plasma, in all intervention groups with p 
value of < 0.001. The comparison of the mean WBC’s 
in between groups at the end of study were statistically 
significant between in all interventions group with 
p<0.01. The TRI E group demonstrated a larger 
reduction in WBC count as compare to TOCO and 
control group (Fig. 1). 
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Figure 1: Pre and post-intervention results of sepsis parameters (PCT, CRP and WBC) and oxidative stress parameter (8-
OHdG/Creatinine), data are expressed as mean ± SD with significant statistical analysis *p<0.05 and **p<0.001. 
 
Oxidative Stress parameter 
 
8-OHdG/Creatinine test results showed significant 
reduction in plasma level in each group when the 
result on admission was compared with the result at 
end of the study. The reduction was significant with p 
value < 0.001 for all three intervention groups. The 
mean of 8-OHdG/Creatinine ratio showed statistical 
significant reduction in comparison between the three 
groups (p<0.01). The TRI E group demonstrated a 
larger reduction in 8-OHdG/Creatinine level as 
compare to TOCO and control group (Fig. 1). 
 
Discussion 
 
The goal of this study was to compare the benefits of 
two types of Vitamin E in SIRS patients. Vitamin E 
tocotrienol isotype was compared with Vitamin E α-
tocopherol isotype (both in the presence of vitamin C) 
for the management of critically ill patients diagnosed 
with SIRS. Previous studies had concentrated on the 
effect of α-tocopherol in the presence of Vitamin C in 
this group of patients (6,7) and Maria et al. (8) showed 
that tocotrienol is a better antioxidant as compared to 
tocopherol in both in vitro and in vivo environments. 
A combination of various clinical and laboratory 
investigations were performed in this study to quantify 
sepsis and oxidative stress parameters.  While other 
studies mainly investigated oxidative stress markers 
and observed 28 days mortality rate and degree of 
organ dysfunction (6,7). The most salient result of our 
study is that the relatively moderate oral dose of 
vitamin E tocotrienol supplementation reduces 
oxidative stress and inflammatory sepsis markers 
(CRP, WBC and 8-OHdG/Creatinine) as compared to 
vitamin E α-tocopherol. However, both vitamin E 
supplementations showed beneficial effect in reducing 
oxidative stress and inflammatory sepsis markers as 
compared to critically ill patients diagnosed with SIRS 
that are not received any supplementation.  
 
In this study we observed significant changes in the 
clinical parameters (heart rate, systolic and diastolic 
blood pressure, urine output, the need of inotropic 
support, respiratory rate and temperature) of the SIRS 
patients in the TRI E and TOCO groups when 
compared to the control. These findings were similar 
with previous study (9), which showed a positive 
association between antioxidant therapy and 
improvements in hemodynamic parameters. Another 
study showed a potential benefit when antioxidants 
were administered early to protect against significant 
organ dysfunction and infection (6). Interestingly, our 
study states that those benefits could be obtained by 
patients with significant co morbidity, included 
varieties of different diagnoses. Earlier, Nathens et al. 
(6) had questioned the benefits of various SIRS 
patients with different varieties of diagnoses and co 
morbidities. Our study results were also consistent 
with those obtained in an experimental model of septic 
shock (10). Our study showed that PCT levels between 
the groups (inter groups) had no significant difference 
although there were significant changes observed 
within each group (intra group results) comparing their 
pre and post interventions levels.  
 
In healthy people, plasma PCT concentrations are 
found to be below 0.05 µg/L, but PCT concentrations 
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can increase up to 1000 µg/L in patients with sepsis, 
severe sepsis or septic shock. PCT levels are usually 
low in viral infections, chronic inflammatory disorders 
or autoimmune processes. PCT compared to other 
parameters has an early and highly specific increase in 
response to bacterial infections and sepsis. Thus, in 
septic conditions increased PCT levels can be 
observed 3-6 hours after infectious challenge (11). The 
most potent stimulator for PCT induction under 
experimental conditions is the systemic effect of 
bacterial endotoxins (12). Plasma PCT is very stable 
and is not degraded to hormonally active calcitonin 
(13). In pulmonary injury and pulmonary infection, the 
circulating concentrations of procalcitonin and other 
calcitonin precursors increase rapidly, probably in 
response to sepsis related cytokine release from 
pulmonary neuroendocrine cells of the bronchial 
epithelium or mononuclear cells (14). Low PCT values 
(<0.25 µg/L) in patients with clinical signs of infection 
indicate a low probability for blood culture proof of 
bacterial infection, whereas elevated PCT values 
(>0.25 µg/L) seem to correlate with the bacterial load 
and positive blood culture result.  PCT levels in sepsis 
are generally greater than 1-2 µg/L and often reach 
values between 10 and 100 µg/L, or considerably 
higher in individual cases, thus enabling the diagnostic 
differentiation between various clinical conditions and 
a severe bacterial infection (11). PCT and CRP both 
are infection-related parameters. However, both 
proteins are also induced during non-infectious causes 
of systemic inflammation (SIRS) and in patients with 
organ dysfunction (15). The process of lipid 
peroxidation seems to correlate with the degree of 
infection as indicate by PCT levels (16). PCT also was 
found as a guide to antimicrobial therapy in patients 
with lower respiratory tract infections (17). PCT is a 
marker suggested for sepsis specifically while CRP 
was more as inflammatory marker. (18,19). Patients 
included in our study were diagnosed with SIRS and 
they may not necessarily had sepsis. 
 
The pathophysiological role of severe oxidative stress 
reactions in SIRS has been demonstrated by 
experimental and clinical studies, in which an increase 
in measured oxidative stress markers are directly 
associated with a decrease in serum antioxidants 
(5,20). In our study, we highlighted that increased 
levels of 8-OHdG/Creatinine as an oxidative stress 
marker correlated with increased levels of PCT, CRP 
and WBC. Oxidative stress reactions induce direct 
oxidative tissue injury by means of peroxidation of 
cellular membranes, oxidation of critical enzymatic 
and structural proteins which in turn activate apoptosis 
(6). Previous studies have shown a potential increase 
in oxidative stress markers in critically ill patients 
(5,20).  In accordance with our data 8-OHdG level 
were dramatically increased in SIRS patients at the 
onset of their illness. It increases dramatically in vivo 
secondary to DNA oxidative stress injury and they are 
decreased in response to antioxidant therapy. We 
demonstrated that 8-OHdG can be considered as an 
important and reliable index for oxidative stress in 
vivo. At present, 8-OHdG is not a diagnostic tool but it 
is used in research to trend changes in protein 
oxidation as it is a ubiquitous byproduct found in all 
normal biological fluids and tissues. Patients who 
received a relatively moderate dose of tocotrienol with 
vitamin C supplementation showed a significant 
reduction in urinary 8OHdG/creatinine level - the 
major byproduct of global oxidative DNA damage in 
the body (21) more than others whom supplied by the 
same relatively moderate dose of α-tocopherol with 
vitamin C. This result could help in explanation of the 
significant changes in sepsis parameters of patients in 
TRI E and TOCO groups as compared to control 
groups by modulating the oxidative stress activities.  
 
In study done by Gutteridge & Mitchell (22), reported 
critically ill patients had very small concentrations of 
vitamin E and C. A prior study investigated high 
circulating oxidative stress markers which correlated 
with both vitamin E concentrations (20) and APACHE 
II scores (5). However, in our study neither vitamin E 
nor C was measured. A relative decrease in antioxidant 
capacity appeared to correlate with the severity of the 
illness and suggested a causal relationship between 
antioxidant depletion and increasing levels of organ 
dysfunction (6). In 2004, Crimi et al (7) stated that 
vitamin E is a nonenzymatic antioxidant present in 
biological membranes, it reacts as a chain breaking 
antioxidant inhibiting peroxidation of lipids and is the 
most important lipid soluble antioxidant in humans. 
Vitamin E and C act synergistically resulting in 
tocopheroxyl and tocotrienoxyl radicals reduced back 
to their original form by Vitamin C. Both studies 
confirmed the circulating plasma levels of their 
antioxidants doses were at accepted therapeutic levels. 
So far our study was conducted according to the 
previous principles. 
 
Our study had a relatively homogenous population as 
one of its strengths which reduces the noise and 
variability and thus increases the likelihood of 
observing a measurable effect. This homogenous was 
established by using the APACHE II score to help 
select relatively patients with same level of illness 
severity. There were no observed side effects 
attributable to the use of antioxidants in our study, and 
administration of relatively moderate dose of 
tocotrienol, tocopherol and vitamin C did not increase 
the risk of renal failure or coagulopathy among the 
patients of this study. 
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Conclusion  
 
This study showed that the relatively moderate dose of 
vitamin E tocotrienol and α-tocopherol with vitamin C 
supplement as an enteral feeding may prevent 
oxidative stress damage to DNA as compared to 
control, in critically ill patients with SIRS as this 
therapy resulted in significant clinical changes by 
which positive association between antioxidant 
therapy and improvements in hemodynamic, 
pulmonary and sepsis parameters. However, the effect 
of vitamin E tocotrienol was more superior to vitamin 
E α-tocopherol. Those benefits could be obtained by 
patients with significant comorbidity, included 
varieties of different diagnoses. This study showed 
that vitamin E in combination with vitamin C have 
therapeutic benefits in the treatment of critically ill 
patients with SIRS. 
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